SFedU is developing a new organic painkiller that is not addictive, informs the centerCenter for Public Communications of the Southern Federal University.

Scientists are conducting fundamental research in the field of organic chemistry and organic synthesis with an eye to obtaining previously unknown compounds that are of interest as biologically active.

  • Further, we offer them to our colleagues for biotesting and studying pharmacological properties, – said Anatoly Morkovnik, Chief Researcher, Doctor of Chemical Sciences, Head of the Laboratory of Organic Synthesis of the Research Institute of Physical and Organic Chemistry of the Southern Federal University. — We work within the framework of a government assignment and a grant from the Russian Foundation for Basic Research.

One of the most relevant and successful results of the work of researchers is the drug under the working name RU-1205, a highly active synthetic experimental analgesic without, which is extremely important, narcogenic potential. After passing the stage of preclinical studies, it needs to conduct a phase of clinical trials with the participation of medical organizations and industrial business structures. According to scientists, among the analgesics used in clinical practice, not a single drug currently has such properties and mechanism of action. The development of scientists is protected by joint patents of the Russian Federation with VolgGMU No. 2412187 and 2413512.

This drug is intended for use in severe pain syndromes associated with injuries, surgeries, diseases of internal organs, myocardial infarction, malignant neoplasms and various chronic diseases. It can find its application in surgery, anesthesiology, obstetrics and gynecology, traumatology, oncology, neurology and cardiology.

  • This problem has a global character: until recently, about 40,000 patients per year died from opiate painkillers in the United States, mainly from a depressant effect on the respiratory center, which is not observed in the case of RU-1205, the scientist noted.

Other experimental drugs developed by the scientists of the two organizations and passed the preclinic are anti-migraine (RU-31), antiplatelet (RU-891) and antiulcer (RU-64). In addition, with the participation of the laboratory, together with Selena LLC, a selenium-correcting substance Selekor was developed based on a synthetic compound with a record low (for selenium compounds) toxicity. It is used in the production of dietary supplements “SelekorMaxi” and “Selegerts”, produced in tablet form. Selenium is very important for the human body, since selenium-containing enzymes are involved in the detoxification process, are important antioxidants, regulate fatty acid oxidation, participate in the synthesis of many hormones, affect reproductive function, have a protective effect on the immune system, and so on.

As part of import substitution and the creation of modern domestic medicines, scientists from the Research Institute of FOH do not explore new reactions, methods of organic synthesis and new organic compounds, and also negotiate with potential partners to conduct the final stages of clinical testing of drugs and their introduction to the Russian market.

Earlier we reported that in the Polytechnic Museum of the Southern Federal University the exhibition “Time and money”.

Photo CSC SFU